A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Matthew C. Cheung, Nicole Mittmann, Carolyn Owen, Nizar Abdel-Samad, Graeme A.M. Fraser, Selay Lam, Michael Crump, Catherine Sperlich, Richard van der Jagt, Anca Prica, Stephen Couban, Jennifer A. Woyach, Amy S. Ruppert, Allison M. Booth, Sumithra J. Mandrekar, Gail McDonald, Lois E. Shepherd, Hope Yen, Bingshu E. Chen, Annette E. Hay

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences